Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1Blood Coagulation Disorders 1Afibrinogenemia 1

Interventions

pembrolizumab 134Carboplatin 134Cisplatin 121Paclitaxel 105Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 74Cyclophosphamide 61Dexamethasone 60Pemetrexed 58Bevacizumab 56durvalumab 55Capecitabine 55Doxorubicin 52Radiotherapy 51Oxaliplatin 50Fluorouracil 49Radiation 48Rituximab 44Leucovorin 44Vincristine 42Lenalidomide 41Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 33Prednisone 31Irinotecan 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × cryoprecipitate coagulum × 90 days × Clear all
NCT06617897 2026-03-11

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

CSL Behring

Phase 3 Recruiting
90 enrolled

Afibrinogenemia, Blood Coagulation Disorders, Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon âš¡